FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093956656> ?p ?o ?g. }

• W3093956656 endingPage "e860" @default.
• W3093956656 startingPage "e860" @default.
• W3093956656 abstract "Commonly used tools for predicting the risk of pelvic lymph node involvement (LNI) in prostate cancer often do not incorporate information on the percentage of positive biopsy cores (PPB). To better inform the use of elective nodal irradiation in the definitive treatment of prostate cancer, we examined the association between PPB and risk of pathologic pelvic LNI in men with prostate cancer who underwent radical prostatectomy (RP). We identified 109,577 men from the National Cancer Database who were diagnosed in 2010-2015 with cN0M0 prostate cancer, had 6-24 cores sampled at biopsy, and underwent RP with pathologic nodal evaluation. Multivariable logistic regression was used to examine the association between PPB and the likelihood of having ≥1 positive pelvic lymph node, adjusting for other known clinicopathologic prognostic variables. Overall, 4.0% (4,340) of the cohort was found to have pelvic LNI at the time of RP. Higher PPB was associated with an increased risk of pelvic LNI (adjusted odds ratio [AOR] 1.75 for 25.1-50.0% PPB, 2.63 for 50.1-75.0% PPB, and 4.49 for 75.1-100.0% PPB vs. ≤25.0% PPB, all P<0.001). Notably, men with Gleason 8 disease and ≤25.0% PPB only had a 3.6% risk of pelvic LNI, whereas men with Gleason 9-10 disease and 75.1-100.0% PPB had a 32.6% risk (Table). Other factors associated with the likelihood of pelvic LNI included a higher biopsy Gleason score (AOR 1.43 for Gleason 8 and 2.84 for Gleason 9-10 vs. Gleason 4+3, both P<0.001), more advanced clinical tumor stage (AOR 1.48 for cT2, 1.97 for cT3, and 3.87 for cT4 vs. cT1, all P<0.001), and a higher PSA (AOR 1.90 for 10.0-19.9 ng/mL, 2.40 for 20.0-39.9 ng/mL, and 2.60 for ≥40.0 ng/mL vs. <10.0 ng/mL, all P<0.001), but not more advanced age (AOR 0.98 for >62 years [median] vs. ≤62 years, P = 0.59) or black vs. white race (AOR 0.99, P = 0.92). There was a statistically significant and clinically relevant association between increasing PPB and a higher risk of pelvic LNI. As the ongoing RTOG 0924 randomized trial matures, clinicians should consider incorporating information on PPB in determining which patients with prostate cancer may benefit from receiving radiation therapy to the pelvic lymph nodes.Abstract 4004; TableThe risk of pelvic lymph node involvement by percentage of positive biopsy cores (PPB) and biopsy Gleason scoreGleason 6Gleason 3+4Gleason 4+3Gleason 8Gleason 9-10PPB ≤25.0%0.1%0.6%2.6%3.6%8.6%PPB 25.1-50%0.3%1.1%4.6%7.2%13.3%PPB 50.1-75.0%0.2%1.9%7.8%11.9%18.9%PPB 75.1-100%0.3%4.0%13.1%17.8%32.6% Open table in a new tab" @default.
• W3093956656 created "2020-10-29" @default.
• W3093956656 creator A5004893863 @default.
• W3093956656 creator A5013277990 @default.
• W3093956656 creator A5018154366 @default.
• W3093956656 creator A5026629222 @default.
• W3093956656 creator A5026756753 @default.
• W3093956656 creator A5040900375 @default.
• W3093956656 creator A5044221282 @default.
• W3093956656 creator A5049584822 @default.
• W3093956656 creator A5064455342 @default.
• W3093956656 creator A5077141876 @default.
• W3093956656 creator A5085720702 @default.
• W3093956656 creator A5086818804 @default.
• W3093956656 date "2020-11-01" @default.
• W3093956656 modified "2023-10-01" @default.
• W3093956656 title "Association Between Percentage of Positive Biopsy Cores and Risk of Pelvic Lymph Node Involvement in Prostate Cancer" @default.
• W3093956656 doi "https://doi.org/10.1016/j.ijrobp.2020.07.427" @default.
• W3093956656 hasPublicationYear "2020" @default.
• W3093956656 type Work @default.
• W3093956656 sameAs 3093956656 @default.
• W3093956656 citedByCount "0" @default.
• W3093956656 crossrefType "journal-article" @default.
• W3093956656 hasAuthorship W3093956656A5004893863 @default.
• W3093956656 hasAuthorship W3093956656A5013277990 @default.
• W3093956656 hasAuthorship W3093956656A5018154366 @default.
• W3093956656 hasAuthorship W3093956656A5026629222 @default.
• W3093956656 hasAuthorship W3093956656A5026756753 @default.
• W3093956656 hasAuthorship W3093956656A5040900375 @default.
• W3093956656 hasAuthorship W3093956656A5044221282 @default.
• W3093956656 hasAuthorship W3093956656A5049584822 @default.
• W3093956656 hasAuthorship W3093956656A5064455342 @default.
• W3093956656 hasAuthorship W3093956656A5077141876 @default.
• W3093956656 hasAuthorship W3093956656A5085720702 @default.
• W3093956656 hasAuthorship W3093956656A5086818804 @default.
• W3093956656 hasConcept C121608353 @default.
• W3093956656 hasConcept C126322002 @default.
• W3093956656 hasConcept C126894567 @default.
• W3093956656 hasConcept C143998085 @default.
• W3093956656 hasConcept C151956035 @default.
• W3093956656 hasConcept C156957248 @default.
• W3093956656 hasConcept C2775934546 @default.
• W3093956656 hasConcept C2776235491 @default.
• W3093956656 hasConcept C2779466945 @default.
• W3093956656 hasConcept C2780192828 @default.
• W3093956656 hasConcept C2780849966 @default.
• W3093956656 hasConcept C29456083 @default.
• W3093956656 hasConcept C71924100 @default.
• W3093956656 hasConcept C72563966 @default.
• W3093956656 hasConceptScore W3093956656C121608353 @default.
• W3093956656 hasConceptScore W3093956656C126322002 @default.
• W3093956656 hasConceptScore W3093956656C126894567 @default.
• W3093956656 hasConceptScore W3093956656C143998085 @default.
• W3093956656 hasConceptScore W3093956656C151956035 @default.
• W3093956656 hasConceptScore W3093956656C156957248 @default.
• W3093956656 hasConceptScore W3093956656C2775934546 @default.
• W3093956656 hasConceptScore W3093956656C2776235491 @default.
• W3093956656 hasConceptScore W3093956656C2779466945 @default.
• W3093956656 hasConceptScore W3093956656C2780192828 @default.
• W3093956656 hasConceptScore W3093956656C2780849966 @default.
• W3093956656 hasConceptScore W3093956656C29456083 @default.
• W3093956656 hasConceptScore W3093956656C71924100 @default.
• W3093956656 hasConceptScore W3093956656C72563966 @default.
• W3093956656 hasIssue "3" @default.
• W3093956656 hasLocation W30939566561 @default.
• W3093956656 hasOpenAccess W3093956656 @default.
• W3093956656 hasPrimaryLocation W30939566561 @default.
• W3093956656 hasRelatedWork W1530684645 @default.
• W3093956656 hasRelatedWork W2054093028 @default.
• W3093956656 hasRelatedWork W2068509057 @default.
• W3093956656 hasRelatedWork W2069299245 @default.
• W3093956656 hasRelatedWork W2078797104 @default.
• W3093956656 hasRelatedWork W2099948048 @default.
• W3093956656 hasRelatedWork W2151006016 @default.
• W3093956656 hasRelatedWork W2590008096 @default.
• W3093956656 hasRelatedWork W894693432 @default.
• W3093956656 hasRelatedWork W93186087 @default.
• W3093956656 hasVolume "108" @default.
• W3093956656 isParatext "false" @default.
• W3093956656 isRetracted "false" @default.
• W3093956656 magId "3093956656" @default.
• W3093956656 workType "article" @default.